



You are invited to

The Use of Biomarkers in the Prediction, Prevention and Diagnosis of Preeclampsia

Learning Outcomes:

1. Describe the role of placental growth factor (PIGF) in first trimester preeclampsia screening.
2. Explain the clinical utility of the sFlt-1/PIGF ratio in the second and third trimester.
3. Summarise appropriate testing for the prediction, prevention and diagnosis of preeclampsia.



Date: Thursday 20th May
Time: 6.00pm to 7.05pm (AEST)
RSVP: Tuesday 18th May
RACGP Activity ID No: 260885

[Click here to register](#)

Webinar Moderator: Dr Lauren Harper, Head of Medical Affairs, Roche Diagnostics.

Agenda

- 6.00 - 6.05pm Introductions – *Dr Lauren Harper*
 6.05 - 6.25pm The Role of Placental Growth Factor in the Prediction of Preeclampsia in the First Trimester – *Prof Jon Hyett*
 6.25 – 6.45pm The Clinical Utility of Preeclampsia Biomarkers in the Second and Third Trimester – *Prof Shaun Brennecke*
 6.45 – 7.05pm Q&A – Facilitated by *Dr Lauren Harper*

Speakers



Professor Hyett
 Head of High Risk Obstetrics at Royal Prince Alfred Women's and Babies (Sydney)

Professor Hyett will outline the current challenges in the clinical management of preeclampsia and discuss the effectiveness and benefits of incorporating placental growth factor into first trimester screening for this serious medical condition.



Professor Brennecke
 Director of the Department of Maternal - Fetal Medicine and Head of its Pregnancy Research Centre at the Royal Women's Hospital (Melbourne)

Professor Brennecke will discuss the sFlt-1/PIGF ratio test as a tool to aid in short-term prediction of preeclampsia and support in the differential diagnosis of the condition, thereby improving the outcome for mother and child through effective clinical management.

For any further information about this educational webinar please contact Eileen Butler on 0418746901 or email australia.womenshealth@roche.com